2W60 Stock Overview
A clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Mustang Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.84 |
| 52 Week High | US$11.06 |
| 52 Week Low | US$4.19 |
| Beta | 1.85 |
| 11 Month Change | 0% |
| 3 Month Change | -3.53% |
| 1 Year Change | -40.63% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -88.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2W60 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.5% | -1.4% |
| 1Y | -40.6% | -16.2% | 11.8% |
Return vs Industry: 2W60 underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: 2W60 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 2W60 volatility | |
|---|---|
| 2W60 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2W60 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 2W60's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 113 | Manny Litchman | www.mustangbio.com |
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment.
Mustang Bio, Inc. Fundamentals Summary
| 2W60 fundamental statistics | |
|---|---|
| Market cap | €46.25m |
| Earnings (TTM) | -€68.20m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs 2W60 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2W60 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$74.42m |
| Earnings | -US$74.42m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.16 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 92.5% |
How did 2W60 perform over the long term?
See historical performance and comparison